In 2017, the Parker Institute for Cancer Immunotherapy (PICI) began a fruitful partnership with the Cancer Research Institute (CRI), their first non-profit partnership. PICI’s clinical trial management, translational resources, and informatics experts coupled with CRI’s history, expertise, and connections in the IO field has resulted in several novel cancer immunotherapy clinical trials, initiatives to improve cancer treatment personalization, and peer-reviewed scientific publications. These initiatives have advanced the field of IO with the aim of improving cancer patient outcomes.
PICI brings together scientists, clinicians, and industry partners to build a smarter and more coordinated cancer immunotherapy research effort. PICI’s foundation is a collaboration between the country’s leading immunologists and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania, and The University of Texas MD Anderson Cancer Center. The PICI network also includes more than 40 industry and nonprofit partners, more than 60 labs, and more than 300 of the nation’s top researchers focused on treating the deadliest cancers.